Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

Brain : a Journal of Neurology
Raúl de la Fuente-FernándezA Jon Stoessl

Abstract

Peak-dose dyskinesias are abnormal movements that usually occur 1 h after oral administration of levodopa, and often complicate chronic treatment of Parkinson's disease. We investigated by PET with [11C]raclopride whether Parkinson's disease progression modifies the striatal changes in synaptic dopamine levels induced by levodopa administration, and whether this modification, if present, could have an impact on the emergence of dyskinesias. We found that, 1 h after oral administration of standard-release 250/25 mg of levodopa/carbidopa, levodopa-induced increases in synaptic dopamine levels (as estimated by striatal changes in [11C]raclopride binding potential) correlated positively with duration of Parkinson's disease symptoms (for the caudate nucleus, r = 0.79, P < 0.001; for the putamen, r = 0.88, P < 0.0001). Patients with peak-dose dyskinesias had larger 1-h increases in synaptic dopamine levels than stable responders, but there were no between-group differences in [11C]raclopride binding 4 h post-levodopa. The corresponding (time x group) interaction term in the repeated measures analysis of covariance was significant, even after adjusting for between-group differences in duration of Parkinson's disease symptoms (for the ...Continue Reading

Citations

Sep 1, 2006·Experimental Brain Research·Sarah LemieuxChristian Duval
Nov 4, 2005·European Journal of Nuclear Medicine and Molecular Imaging·Deniz KirikPhilippe Hantraye
Feb 3, 2012·Journal of Neurology·Marios Politis, Paola Piccini
Jul 2, 2008·Current Neurology and Neuroscience Reports·Shyamal H MehtaKapil D Sethi
Jan 29, 2011·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·A Jon Stoessl
Sep 4, 2008·Journal of the International Neuropsychological Society : JINS·Berta Pascual-SedanoIgnasi Gich
Aug 26, 2006·Nature Clinical Practice. Neurology·C Warren OlanowFabrizio Stocchi
Apr 5, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Matthäus WilleitShitij Kapur
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Ayse UlusoyDeniz Kirik
Dec 9, 2008·Journal of Neurotrauma·Oliver MaricVolker Dietz
Nov 10, 2010·Brain : a Journal of Neurology·Maria C Rodriguez-OrozJose A Obeso
Mar 5, 2011·Brain : a Journal of Neurology·Imtiaz AhmedDavid J Brooks
May 4, 2012·Cold Spring Harbor Perspectives in Medicine·Martin NiethammerDavid Eidelberg
Jul 31, 2007·The Journal of Pharmacology and Experimental Therapeutics·Daniel B PuttermanSteven W Johnson
Jan 4, 2013·PloS One·Tina WeisChristiane M Thiel
Mar 12, 2008·Reviews in the Neurosciences·Susanne NikolausHans-Wilhelm Müller
Apr 18, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Shigeki HiranoDavid Eidelberg
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Mohammad S AlavijehAlan M Palmer
May 25, 2011·Drug Design, Development and Therapy·Patrick Hickey, Mark Stacy
Nov 12, 2014·Nature Reviews. Neurology·Marios Politis
Feb 18, 2014·The Journal of Clinical Investigation·Marios PolitisPaola Piccini
Oct 28, 2008·Brain : a Journal of Neurology·Ana MuñozManolo Carta
Mar 19, 2014·Journal of Molecular Neuroscience : MN·Natalie KaplanSharon Hassin-Baer
Jul 19, 2014·Brain : a Journal of Neurology·Roberto CiliaGianni Pezzoli
Oct 19, 2011·Parkinson's Disease·Sylvia Navailles, Philippe De Deurwaerdère
Aug 18, 2006·Current Opinion in Neurology·Thilo van Eimeren, Hartwig Roman Siebner
Jun 6, 2009·Current Opinion in Neurology·Philippe Damier
Jul 9, 2010·Current Opinion in Neurology·Silke Appel-CresswellMartin J McKeown
Aug 9, 2006·Expert Review of Neurotherapeutics·Alan Diamond, Joseph Jankovic
Jan 13, 2015·Expert Review of Neurotherapeutics·Pantelis StathisAngelo Antonini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.